WO2002098416A3 - Antineoplastic combinations - Google Patents

Antineoplastic combinations Download PDF

Info

Publication number
WO2002098416A3
WO2002098416A3 PCT/US2002/016737 US0216737W WO02098416A3 WO 2002098416 A3 WO2002098416 A3 WO 2002098416A3 US 0216737 W US0216737 W US 0216737W WO 02098416 A3 WO02098416 A3 WO 02098416A3
Authority
WO
WIPO (PCT)
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
antinoeplastic
neoplasms
Prior art date
Application number
PCT/US2002/016737
Other languages
French (fr)
Other versions
WO2002098416A2 (en
Inventor
Gary Dukart
James Joseph Gibbons Jr
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020037015721A priority Critical patent/KR100875611B1/en
Priority to EP02729310A priority patent/EP1392286A2/en
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to CA002447732A priority patent/CA2447732A1/en
Priority to HU0400006A priority patent/HUP0400006A2/en
Priority to BR0210101-7A priority patent/BR0210101A/en
Priority to IL15880002A priority patent/IL158800A0/en
Priority to JP2003501455A priority patent/JP2004532883A/en
Priority to UA20031212939A priority patent/UA78706C2/en
Priority to NZ529877A priority patent/NZ529877A/en
Priority to AU2002259309A priority patent/AU2002259309B2/en
Priority to EA200301319A priority patent/EA007530B1/en
Priority to MXPA03010907A priority patent/MXPA03010907A/en
Publication of WO2002098416A2 publication Critical patent/WO2002098416A2/en
Publication of WO2002098416A3 publication Critical patent/WO2002098416A3/en
Priority to NO20035317A priority patent/NO20035317L/en
Priority to AU2008202690A priority patent/AU2008202690A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides the use of a combination of an mTOR inhibitor and an antinoeplastic alkylating agent in the treatment of neoplasms.
PCT/US2002/016737 2001-06-01 2002-05-29 Antineoplastic combinations WO2002098416A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
NZ529877A NZ529877A (en) 2001-06-01 2002-05-29 Antineoplastic combinations
UA20031212939A UA78706C2 (en) 2001-06-01 2002-05-29 Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
CA002447732A CA2447732A1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations
EP02729310A EP1392286A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations
BR0210101-7A BR0210101A (en) 2001-06-01 2002-05-29 Antineoplastic Combinations
IL15880002A IL158800A0 (en) 2001-06-01 2002-05-29 Antineoplastic combinations
AU2002259309A AU2002259309B2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations
KR1020037015721A KR100875611B1 (en) 2001-06-01 2002-05-29 Products containing mTor inhibitors and anti-neoplastic alkylating agents
HU0400006A HUP0400006A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations
JP2003501455A JP2004532883A (en) 2001-06-01 2002-05-29 Anti-tumor combination
EA200301319A EA007530B1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations
MXPA03010907A MXPA03010907A (en) 2001-06-01 2002-05-29 Antineoplastic combinations.
NO20035317A NO20035317L (en) 2001-06-01 2003-11-28 Antineoplastic combinations
AU2008202690A AU2008202690A1 (en) 2001-06-01 2008-06-18 Antineoplastic combination

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29519001P 2001-06-01 2001-06-01
US29523601P 2001-06-01 2001-06-01
US60/295,236 2001-06-01
US60/295,190 2001-06-01

Publications (2)

Publication Number Publication Date
WO2002098416A2 WO2002098416A2 (en) 2002-12-12
WO2002098416A3 true WO2002098416A3 (en) 2003-03-13

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (en)
JP (1) JP2004532883A (en)
KR (1) KR100875611B1 (en)
CN (1) CN100496485C (en)
AU (2) AU2002259309B2 (en)
BR (1) BR0210101A (en)
CA (1) CA2447732A1 (en)
CO (1) CO5540294A2 (en)
EA (1) EA007530B1 (en)
HU (1) HUP0400006A2 (en)
IL (1) IL158800A0 (en)
MX (1) MXPA03010907A (en)
NO (1) NO20035317L (en)
NZ (1) NZ529877A (en)
PL (1) PL367267A1 (en)
SG (1) SG153647A1 (en)
WO (1) WO2002098416A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3406249A1 (en) * 2001-02-19 2018-11-28 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor
UA83484C2 (en) * 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
AR046194A1 (en) 2003-11-04 2005-11-30 Mayo Foundation TREATMENT METHOD OF MANTO CELL LYMPHOMA
CN113975393A (en) 2005-02-03 2022-01-28 综合医院公司 Methods of treating gefitinib resistant cancers
CA2626326C (en) * 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2006314444C1 (en) * 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
BRPI0709750A2 (en) * 2006-04-05 2011-07-26 Novartis Ag combinations of therapeutic agents for cancer treatment
NZ621972A (en) * 2007-03-07 2015-09-25 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
NZ600982A (en) 2008-06-17 2014-01-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
DK2326329T3 (en) 2008-08-04 2017-02-20 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN105999264A (en) 2009-04-06 2016-10-12 惠氏有限责任公司 Treatment regimen utilizing neratinib for breast cancer
CN103721189A (en) * 2013-12-27 2014-04-16 刘玉含 Meningeoma nursing medicine and preparation method thereof
CN105168204A (en) * 2015-09-06 2015-12-23 江志鑫 Pharmaceutical composition containing mitomycin and capable of resisting colon cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
EP0525960A1 (en) * 1991-06-18 1993-02-03 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
WO2002040000A2 (en) * 2000-11-15 2002-05-23 Wyeth Use of cci-779 as an antineoplastic agent
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
EP0525960A1 (en) * 1991-06-18 1993-02-03 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
WO2002040000A2 (en) * 2000-11-15 2002-05-23 Wyeth Use of cci-779 as an antineoplastic agent
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONI J ET AL: "PHARMACOKINETICS OF ESCALATING DOSES OF CCI-779 IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH ADVANCED SOLID TUMORS", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, VOL. 37, NR. SUPPL 6, PAGE(S) S68, ISSN: 0959-8049, XP001084492 *
GEOERGER B ET AL: "ANTITUMOR ACTIVITY OF THE RAPAMYCIN ANALOG CCI-779 IN HUMAN PRIMITIVE NEUROECTODERMAL TUMOR/MEDULLOBLASTOMA MODELS AS SINGLE AGENT AND IN COMBINATION CHEMOTHERAPY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 4, no. 61, 15 February 2001 (2001-02-15), pages 1527 - 1532, XP001079526, ISSN: 0008-5472 *
SHI Y ET AL: "Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.", CANCER RESEARCH, (1995 MAY 1) 55 (9) 1982-8., vol. 55, no. 9, - 1995, pages 1982 - 8, XP002040888 *

Also Published As

Publication number Publication date
KR20040025923A (en) 2004-03-26
EP1392286A2 (en) 2004-03-03
IL158800A0 (en) 2004-05-12
AU2008202690A1 (en) 2008-07-10
WO2002098416A2 (en) 2002-12-12
EA007530B1 (en) 2006-10-27
CO5540294A2 (en) 2005-07-29
PL367267A1 (en) 2005-02-21
KR100875611B1 (en) 2008-12-24
BR0210101A (en) 2004-06-08
NZ529877A (en) 2006-08-31
MXPA03010907A (en) 2004-02-17
CN1646120A (en) 2005-07-27
HUP0400006A2 (en) 2004-04-28
AU2002259309B2 (en) 2008-05-01
CA2447732A1 (en) 2002-12-12
CN100496485C (en) 2009-06-10
SG153647A1 (en) 2009-07-29
JP2004532883A (en) 2004-10-28
NO20035317L (en) 2003-12-22
NO20035317D0 (en) 2003-11-28
EA200301319A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
WO2002040000A3 (en) Use of cci-779 as an antineoplastic agent
SG170612A1 (en) Antineoplastic combinations
WO2002098416A3 (en) Antineoplastic combinations
IL157898A0 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
WO2004093854A3 (en) Antineoplastic combinations
ECSP056001A (en) ANTINEOPLASTIC COMBINATIONS
MXPA03005298A (en) Gyrase inhibitors and uses thereof.
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2002323180A1 (en) Hydroxypyridonate and hydroxypyrimidinone chelating agents
EP1350431A4 (en) Method of selecting antimicrobial agent and method of using the same
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
ECSP034866A (en) ANTINEOPLASTIC COMBINATIONS
AR033012A1 (en) ANTINEOPLASIC COMBINATIONS
HK1050609A1 (en) Insecticide transpiration apparatus and kit for the same
EP1511753A4 (en) Antimicrobial agents and uses thereof
AU2002234165A1 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002083151A3 (en) Compositions and methods for treating an arthritic condition
MXPA03007596A (en) 1k-polyurethane lacquer and use thereof.
EP1412754A4 (en) Diagnostic methods and agents
GB0122162D0 (en) Agent
GB0106987D0 (en) Immunotherapeuitic agent
AU7602100A (en) Method for the identification of agents that inhibit or promote cataracts and uses thereof
AU2002364385A1 (en) Implantable device and the use thereof
AUPR311901A0 (en) Integrated toilet suite and bidette combination
AU2002259301A1 (en) Caspase inhibitors and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002729310

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 158800

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1475/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002259309

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2447732

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 03104435

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/010907

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003501455

Country of ref document: JP

Ref document number: 02811048X

Country of ref document: CN

Ref document number: 529877

Country of ref document: NZ

Ref document number: 1020037015721

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003/09816

Country of ref document: ZA

Ref document number: 200309816

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200301319

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2002729310

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642